Galatea Bio and Fabric Genomics have entered a strategic partnership to develop genetic disease risk assays integrating polygenic risk scores (PRS) with clinical gene panel interpretation. Initially focusing on an inherited cardiovascular gene panel including traits like coronary artery disease and hypertension, the collaboration plans to expand to hereditary cancer panels encompassing breast, colorectal, and prostate cancers. This integration of rare variant and polygenic data aims to deliver enhanced personalized risk insights across diverse populations, supported by recent funding and genomic database expansion efforts focusing on non-European ancestries.